What iNGENū CRO does

iNGENū CRO is a full-service, physician-owned and physician-led clinical research organization headquartered in Australia (Sydney), delivering clinical and non-clinical research services to biotech and pharmaceutical sponsors globally. The company offers an integrated service stack spanning clinical operations, data management, biostatistics, regulatory affairs, medical writing, medical monitoring, central reading room, and endpoint adjudication, with every study directed by a board-certified medical specialist rather than managed by generalist project coordinators.

Underpinning the service delivery is a proprietary in-house technology platform architected from inception as a technology-native CRO. The platform integrates real-time reporting, risk-based quality management, continuous self-audited quality systems, and a fully integrated eClinical suite, and is the basis for the company's milestone-based fixed pricing model in which sponsors pay for outcomes delivered rather than hours consumed. The stated cost structure is 80-90% below comparable US CRO pricing.

iNGENū operates seven offices across five regions (Australia, UK, Malaysia, Singapore, India, Philippines, USA), runs 40+ studies concurrently, and targets complex therapeutic areas including oncology, neuroscience, ophthalmology, cell and gene therapy, cannabinoid and psychedelic compounds, rare and orphan diseases, and early-stage clinical trials. Named customers span early-stage biotech (Avata Bio, Grey Matter Pharma) and large-cap pharma (Jazz Pharmaceuticals, GW Pharmaceuticals). In November 2025 the company launched a new Global Clinical Trial Model designed to standardize decentralized, multi-region execution at up to 90% cost reduction versus US benchmarks. The company received the Frost & Sullivan 2026 Asia-Pacific Biotech CRO Customer Value Leadership Award.

Name

iNGENū CRO

Legal name

iNGENū Clinical Research Organisation Pty Ltd

Website

https://ingenucro.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Biostatistics services
• Regulatory affairs services

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO offering clinical operations, data management, biostatistics, regulatory affairs, medical writing, medical monitoring, central reading room, and endpoint adjudication. Revenue generated through milestone-based billing where sponsors pay for outcomes delivered rather than hours consumed.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

iNGENū CRO is a physician-led clinical research organization that provides full-service clinical trial services for biotech and pharma sponsors globally. The company delivers clinical operations, data management, biostatistics, regulatory affairs, medical writing, medical monitoring, central reading room, and endpoint adjudication services to support end-to-end trial execution.

Product overview

iNGENū CRO is a full-service, physician-led clinical research organization offering integrated service modules delivered through a proprietary in-house technology platform. The company provides clinical operations, data management, biostatistics, regulatory affairs, medical writing, medical monitoring, Central Reading Room, and endpoint adjudication services. Every study is directed by board-certified medical specialists. The proprietary technology platform underpins all services with real-time reporting, risk-based quality management, and an integrated eClinical suite, enabling fixed milestone-based pricing rather than hourly billing.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Operations End-to-end clinical trial operations services for biotech and pharma sponsors running studies globally.

Quantifiable outcome

• 80-90% cost reduction compared to US CRO pricing
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Sapu NanocoreStrategic or Co-development PartnerSapu Nano is a joint venture between Oncotelic Therapeutics and Dragon Oversea, in which iNGENū CRO serves as the clinical research partner. iNGENū CRO is providing clinical trial execution services for Sapu Nano's investigational Deciparticle™ everolimus (Sapu003) Phase 1 clinical trial for advanced mTOR-sensitive solid tumors including HR+/HER2- breast cancer, renal cell carcinoma, neuroendocrine tumors, TSC-associated tumors, and hepatocellular carcinoma.
• Dragon OverseacoreStrategic or Co-development PartnerDragon Oversea is the joint venture partner with Oncotelic Therapeutics in forming Sapu Nano. As part of the Sapu Nano joint venture, Dragon Oversea collaborates with iNGENū CRO for clinical trial execution of investigational nanomedicine products.
• Oncotelic TherapeuticscoreStrategic or Co-development PartnerOncotelic Therapeutics is the parent company of Sapu Nano joint venture and partners with iNGENū CRO for clinical development of novel nanomedicine therapeutics including Deciparticle™ formulations for cancer treatment.

Scale indicators4 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Novotech: Asia-Pacific-headquartered, mid-sized CRO with comparable focus on biotech sponsors, full-service clinical operations, and cost-efficient geographic delivery. Closest like-for-like peer given shared Australian/Asian roots and biotech-skewed sponsor base.
• Medpace: Mid-sized, physician-led CRO with full-service clinical operations, proprietary technology, and a science-driven operating model. Highly comparable on physician-led differentiation, full-service scope, and growth-oriented positioning versus Tier-1 giants.
• Worldwide Clinical Trials: Mid-tier global CRO focused on complex therapeutic areas and biotech/pharma sponsors. Comparable on full-service scope, mid-market positioning, and emphasis on scientific rigor and specialty expertise.
• Clinical Network Services (CNS): Australia-based CRO offering clinical operations and biometrics to biotech sponsors in the Asia-Pacific region. Direct regional competitor with overlapping customer base and similar cost-disciplined positioning.

Broad incumbents

• IQVIA: Largest global CRO with full-service capabilities across all phases and therapeutic areas. Sets the cost and capability benchmark that iNGENū's 80–90% cost advantage is measured against; represents the primary alternative for enterprise sponsors.
• ICON plc: Tier-1 global CRO with comprehensive clinical, labs, and consulting services. Competes for the same biotech and pharma sponsors but at materially higher price points and broader scale than iNGENū.
• Parexel International: Large global full-service CRO with deep biotech and pharma sponsor relationships. Overlaps with iNGENū on full-service clinical operations but operates at substantially greater scale and pricing.
• Syneos Health: Global biopharmaceutical solutions organization combining CRO services with commercial capabilities. Competes for the same biotech/pharma sponsors with broader service breadth but less specialty / physician-led differentiation.

Emerging players

• Veristat: Specialty CRO focused on complex oncology, rare disease, and advanced therapy trials. Comparable to iNGENū on therapeutic specialization (especially oncology and cell & gene therapy) and biotech-sponsor focus.

Regional players

• Linear Clinical Research: Australia-based early-phase clinical research organization running Phase 1 trials in oncology and other specialties. Direct regional overlap on Australian Phase I capability and biotech sponsor relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iNGENū CRO